Thoracic Mesothelium

Protocol applies to malignant thoracic mesothelioma.

Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition

Procedures

• Cytology (No Accompanying Checklist)
• Incisional Biopsy
• Resection

Authors
Alberto M. Marchevsky, MD
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California

Andrew Folpe, MD
Department of Pathology, Emory University Hospital, Atlanta, Georgia

Mahul B. Amin, MD
Department of Pathology, Emory University Hospital, Atlanta, Georgia
For the Members of the Cancer Committee, College of American Pathologists

Previous contributors: Gerald Nash, MD; Christopher N. Otis, MD
© 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
Summary of Changes to Checklist(s)

Protocol revision date: January 2005

The following changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Pleura / Pericardium Resection Checklist

Macroscopic

Tumor Configuration and Size: the “Cannot be determined” data element was expanded, as shown below

*Tumor Configuration and Size (check all that apply)
  *___ Localized
    *Greatest dimension: ___ cm
    *Additional dimensions: ___ x ___ cm
  *___ Diffuse
    *Maximum thickness: ___ cm
  *___ Tumor configuration cannot be determined (see Comment)
  *___ Tumor size cannot be determined (see Comment)
Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to malignant mesothelioma only
Based on AJCC/UICC TNM, 6th edition

PLEURA/PERICARDIUM: Biopsy

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Percutaneous needle biopsy
___ Thoracoscopic biopsy
___ Open thoracotomy
___ Lymph node biopsy
___ Other (specify): ____________________________
___ Not specified

Tumor Site (check all that apply)
___ Right pleura
___ Left pleura
___ Pericardium
___ Other (specify): ____________________________
___ Not specified

MICROSCOPIC

Histologic Type
___ Epithelioid (epithelial) mesothelioma
___ Sarcomatoid mesothelioma
___ Biphasic mesothelioma
___ Desmoplastic mesothelioma
___ Other (specify): ____________________________
___ Mesothelioma, type cannot be determined

Extent of Invasion (as appropriate)
___ Cannot be determined
___ Lung parenchyma
___ Endothoracic fascia
___ Soft tissue of chest wall
___ Diaphragm
___ Other (specify): ____________________________

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
*Additional Pathologic Findings (check all that apply)
*___ None identified
*___ Ferruginous bodies
*___ Pleural plaque
*___ Pulmonary interstitial fibrosis
*___ Inflammation (type): ____________________________
*___ Other (specify): ____________________________

*Comment(s)

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to malignant mesothelioma only
Based on AJCC/UICC TNM, 6th edition

PLEURA/PERICARDIUM: Resection

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Pleural resection
___ Pericardial resection
___ Other (specify): ____________________________
___ Not specified

Tumor Site (check all that apply)
___ Right pleura
___ Left pleura
___ Pericardium
___ Other (specify): ____________________________
___ Not specified

*Tumor Configuration and Size (check all that apply)
*___ Localized
   *Greatest dimension: ___ cm
   *Additional dimensions: ___ x ___ cm
*___ Diffuse
   *Maximum thickness: ___ cm
*___ Tumor configuration cannot be determined (see Comment)
*___ Tumor size cannot be determined (see Comment)
MICROSCOPIC

Histologic Type
___ Epithelioid (epithelial) mesothelioma
___ Sarcomatoid mesothelioma
___ Biphasic mesothelioma
___ Desmoplastic mesothelioma
___ Other (specify): ____________________________
___ Mesothelioma, type cannot be determined

Pathologic Staging (pTNM)

Primary Tumor (pT)
___ pTX: Primary tumor cannot be assessed
___ pT0: No evidence of primary tumor
___ pT1: Tumor involves ipsilateral parietal pleura, with or without focal involvement of visceral pleura
___ pT1a: Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura. No involvement of the visceral pleura
___ pT1b: Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura, with focal involvement of the visceral pleura
___ pT2: Tumor involves any of the ipsilateral pleural surfaces with at least 1 of the following: confluent visceral pleural tumor (including fissure), invasion of diaphragmatic muscle, invasion of lung parenchyma
___ pT3: Tumor involves any of the ipsilateral pleural surfaces, with at least 1 of the following: invasion of the endothoracic fascia, invasion into mediastinal fat, solitary focus of tumor invading the soft tissues of the chest wall, non-transmural involvement of the pericardium
___ pT4: Tumor involves any of the ipsilateral pleural surfaces, with at least 1 of the following: diffuse or multifocal invasion of soft tissues of the chest wall, any involvement of rib, invasion through the diaphragm to the peritoneum, invasion of any mediastinal organ(s), direct extension to the contralateral pleura, invasion into the spine, extension to the internal surface of the pericardium, pericardial effusion with positive cytology, invasion of the myocardium, invasion of the brachial plexus

Regional Lymph Nodes (pN)
___ pNX: Regional lymph nodes cannot be assessed
___ pN0: No regional lymph node metastases
___ pN1: Metastases in the ipsilateral bronchopulmonary and/or hilar lymph node(s)
___ pN2: Metastases in the subcarinal lymph node(s) and/or the ipsilateral internal mammary or mediastinal lymph node(s)
___ pN3: Metastases in the contralateral mediastinal, internal mammary, or hilar lymph node(s) and/or the ipsilateral or contralateral supraclavicular or scalene lymph node(s)
Specify: Number examined: ___
Number involved: ___

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Distant Metastasis (pM)
___ pMX: Cannot be assessed
___ pM1: Distant metastasis
   *Specify site(s), if known: ____________________________

Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)
___ Absent
___ Present
___ Indeterminate

Margins
___ Cannot be assessed
___ Margins uninvolved by mesothelioma
   Distance of tumor from closest margin: ___ mm
   Specify margin: ____________________________
___ Margin(s) involved by mesothelioma
   Specify margin(s): ____________________________

*Additional Pathologic Findings (check all that apply)
*___ None identified
*___ Ferruginous bodies
*___ Pleural plaque
*___ Pulmonary interstitial fibrosis
*___ Inflammation (type): __________________________
*___ Other (specify): __________________________

*Comment(s)
Background Documentation

Protocol revision date: January 2005

I. Cytologic Material
A. Clinical Information
1. Patient identification
   a. Name
   b. Identification number
   c. Age (birth date)
   d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
   a. Relevant history
      (1) present/past occupation
      (2) asbestos exposure
      (3) radiation exposure
      (4) previous diagnosis of cancer or active infection
      (5) previous treatment
   b. Relevant findings
      (1) pleural effusion(s) (duration)
      (2) pleural plaque(s) or thickening
      (3) imaging studies
   c. Clinical diagnosis
   d. Procedure (eg, thoracentesis, percutaneous fine-needle aspiration, thoracoscopy)
   e. Operative findings
   f. Anatomic site of specimen (eg, pleural space, including laterality; pericardial space)
   g. Type of specimen (eg, pleural fluid, pleural-based mass)
B. Macroscopic Examination
1. Specimen
   a. Unfixed/fixed (specify fixative)
   b. Number of slides received, if appropriate
   c. Quantity and appearance of fluid specimen, if appropriate (including viscosity)
   d. Other (eg, cytologic preparation from tissue)
   e. Results of intraprocedural consultation
2. Material prepared for microscopic evaluation (eg, smear, cytocentrifuge, thin preparation of fluid, cell block)
3. Special studies (specify) (eg, immunohistochemistry, electron microscopy) (Note A)
C. Microscopic Evaluation
1. Adequacy of specimen (if unsatisfactory for evaluation, specify reasons)
2. Tumor, if present
   a. Histologic type, if possible (Note B)
   b. Other features (eg, necrosis)
3. Additional pathologic findings, if present (eg, ferruginous bodies)
4. Results/status of special studies (specify) (eg, immunohistochemistry, electron microscopy) (Note A)
5. Comments
   a. Correlation with intraprocedural consultation, as appropriate
   b. Correlation with other specimens, as appropriate
   c. Correlation with clinical information, as appropriate
II. Incisional Biopsy
A. Clinical Information
   1. Patient identification
      a. Name
      b. Identification number
      c. Age (birth date)
      d. Sex
   2. Responsible physician(s)
   3. Date of procedure
   4. Other clinical information
      a. Relevant history
         (1) present/past occupation
         (2) asbestos exposure
         (3) radiation exposure
         (4) previous diagnosis of cancer or active infection
         (5) previous treatment
      b. Relevant findings
         (1) pleural effusion(s) (duration)
         (2) pleural plaque(s) or thickening
         (3) imaging studies
      c. Clinical diagnosis
      d. Procedure (eg, percutaneous needle biopsy, thoracoscopic biopsy of
         pleura and/or lung, open thoracotomy biopsy of pleura and/or lung, lymph
         node biopsy)
      e. Operative findings
      f. Anatomic site(s) of specimen (eg, parietal/visceral pleura; lung, indicating
         lobe and laterality; mediastinal node; diaphragm; pericardium)
      g. Type(s) of specimen (eg, pleura, lung, lymph node, tumor nodule)
B. Macroscopic Examination
   1. Specimen
      a. Unfixed/fixed (specify fixative)
      b. Size (3 dimensions)
      c. Descriptive features (color, hemorrhage, necrosis)
      d. Results of intraoperative consultation
   2. Tissue submitted for microscopic evaluation
      a. Submit entire specimen, if possible
      b. Frozen section tissue fragment(s) (unless saved for special studies)
   3. Special studies (specify) (eg, immunohistochemistry, electron microscopy)
      (Note A)
C. Microscopic Evaluation
   1. Tumor
      a. Histologic type (Note B)
      b. Extent of invasion (Note C)
   2. Additional pathologic findings, if present
      a. Ferruginous bodies
      b. Pleural plaque(s)
      c. Pulmonary interstitial fibrosis
      d. Other(s)
   3. Other tissue(s) present
   4. Results/status of special studies (specify)
5. Comments
   a. Correlation with intraoperative consultation, as appropriate
   b. Correlation with other specimens, as appropriate
   c. Correlation with clinical information, as appropriate

III. Resection
   A. Clinical Information
      1. Patient identification
         a. Name
         b. Identification number
         c. Age (birth date)
         d. Sex
      2. Responsible physician(s)
      3. Date of procedure
      4. Other clinical information
         a. Relevant history
            (1) present/past occupation
            (2) asbestos exposure
            (3) radiation exposure
            (4) previous diagnosis of cancer or active infection
            (5) previous treatment
         b. Relevant findings
            (1) pleural effusion(s) (duration)
            (2) pleural plaque(s) or thickening
            (3) imaging studies
         c. Clinical diagnosis
         d. Procedure
         e. Operative findings
         f. Anatomic site(s) of specimen
   B. Macroscopic Examination
      1. Specimens
         a. Organ(s)/tissue(s) included
         b. Unfixed/fixed (specify fixative)
         c. Size (3 dimensions)
         d. Weight
         e. External aspect (extent of resection)
         f. Visceral pleura, as appropriate
         g. Attached tissue, as appropriate (eg, pleura, pericardium, diaphragm, chest wall)
         h. Orientation, if designated by surgeon
         i. Results of intraoperative consultation
      2. Tumor
         a. Location
         b. Size (3 dimensions and minimum/maximum thickness of involved pleura)
         c. Descriptive features (eg, color, diffuse/localized/circumscribed, consistency, other)
         d. Extent of invasion, as appropriate (Note C)
      3. Margins (resections performed for surgical cure)
         a. Bronchus
         b. Pulmonary vessels
c. Parietal pleura
   (1) chest wall
   (2) mediastinal (including pericardium, great vessels, esophagus, trachea, vertebral bodies)

d. Diaphragm
e. Extra-pleural chest wall (including excised thoracoscopic site and old scars)
f. Note areas designated by surgeon

4. Other pleura/lung
   a. Normal
   b. Abnormal (specify)

5. Regional lymph nodes
   a. Total number
   b. Number involved by tumor
      (1) extracapsular extension
      (2) distinguish metastasis from nodal involvement by direct extension, as appropriate

   # All nodes included in a pulmonary specimen are designated N1 (Note E) unless otherwise specified by surgeon

6. Separately submitted lymph nodes (report each node station separately)
   a. Location (station) specified by surgeon
   b. Total number
   c. Number involved by tumor
      (1) extracapsular extension
      (2) distinguish metastasis from nodal involvement by direct extension, as appropriate

7. Tissues submitted for microscopic evaluation
   a. Tumor relation to pleura
   b. Tumor relation to adjacent lung
   c. Tumor relation to extrapleural tissues
      (1) chest wall
      (2) diaphragm
      (3) pericardium
      (4) mediastinal tissues
   d. Margins, as appropriate
      (1) bronchus
      (2) pulmonary vessels
      (3) parietal pleura
         i. chest wall
         ii. mediastinal (pericardium, great vessels, esophagus, trachea, vertebral bodies)
      (4) diaphragm
      (5) extra-pleural chest wall
      (6) areas marked by surgeon
   e. Non-neoplastic pleura/lung
      (1) normal
      (2) abnormal
   f. Attached tissue
   g. All lymph nodes
   h. Frozen section tissue fragment(s) (unless saved for special studies)
      i. Other(s) (specify)

8. Special studies (specify) (eg, immunohistochemistry, electron microscopy)
   (Note A)
C. Microscopic Evaluation

1. Tumor
   a. Histologic type (Note B)
   b. Site (laterality, visceral/parietal pleura, pericardium)
   c. Size (from gross description, diffuse/localized)
   d. Extent of invasion and stage (Note C)

2. Regional lymph nodes
   a. Site(s)
      (1) included in pulmonary specimen
      (2) separately submitted (report each node station separately, as specified)
   b. Number
      (1) total number
      (2) number with metastasis (note extracapsular invasion, if present)

3. Margins
   a. Bronchus
   b. Pulmonary vessels
   c. Parietal pleura
      (1) chest wall
      (2) mediastinal
         i. pericardium
         ii. great vessels
         iii. esophagus
         iv. trachea
         v. vertebral bodies
   d. Diaphragm
   e. Extra-pleural chest wall (including excised thoracoscopic site and old scars)
   f. Areas marked by surgeon

4. Additional pathologic findings, if present
   a. Non-neoplastic lung
   b. Ferruginous bodies
   c. Pleural plaque
   d. Interstitial fibrosis
   e. Other(s)

5. Distant metastasis, specify site(s)

6. Other tissue(s)/organ(s)

7. Results/status of special studies (specify)

8. Comments
   a. Correlation with intraoperative consultation, as appropriate
   b. Correlation with other specimens, as appropriate
   c. Correlation with clinical information, as appropriate

Explanatory Notes

A. Special Studies
Histochemistry, immunohistochemistry and electron microscopy have become important adjuncts to routine microscopic evaluation in the diagnosis and classification of malignant mesothelioma. These methods are helpful to distinguish malignant epithelioid mesothelioma from metastatic adenocarcinoma and sarcomatoid mesothelioma from metastatic or primary pleural sarcomas. These methods are less helpful to distinguish malignancies from reactive mesothelial hyperplasia.
Histochemistry
Adenocarcinomas can have intracytoplasmic neutral mucin that stains with mucicarmine and D-PAS stains. These reactions are usually negative in malignant mesothelioma. The cells of epithelioid mesotheliomas can contain acid mucopolysaccharides that can be stained with Alcian blue or Colloidal iron stains. These reactions can be blocked with the addition of hyaluronidase, confirming the presence of hyaluronic acid in the cytoplasm of mesothelial cells.

Immunohistochemistry
Malignant mesotheliomas usually exhibit cytoplasmic keratin, EMA, thrombomodulin, WT1, cytokeratin 5/6 and calretinin immunoreactivity. Immunostains for CEA, B72.3, BER-EP4, Leu-M1 and other markers for glycoproteins are negative in malignant mesotheliomas and can decorate the cytoplasm of adenocarcinoma cells. Nuclear immunoreactivity for TTF-1 can also be helpful to distinguish malignant mesothelioma, which stains negatively, from pulmonary adenocarcinomas. The tumor cells of sarcomatoid mesotheliomas usually exhibit focal cytoplasmic immunoreactivity for keratin, a finding that can be helpful to distinguish them from pleural sarcomas.

B. Histologic Type
For consistency in reporting, the histologic classification published by the World Health Organization (WHO) is recommended. However, other classifications have been proposed, such as the detailed histologic classification of malignant mesothelioma by Hammar.

WHO Classification of Mesothelial Tumors
Benign
- Adenomatoid tumor
Malignant mesothelioma
- Epithelioid mesothelioma
- Sarcomatoid mesothelioma
- Desmoplastic mesothelioma
- Biphasic mesothelioma
- Tumors with heterologous elements (chondroid, osteoblastic, rhabdomyoblastic, neurogenic sarcoma-like)
- Adenomatoid tumor-like
- Lymphohistocytoid
- Myxoid stroma deciduoid
- Multicystic
- Clear cell
- Small cell
- Poorly differentiated or anaplastic

C. Tumor Stage
The protocol recommends the American Joint Committee (AJCC) and the International Union Against Cancer (UICC) TNM staging system shown below. The AJCC has adopted the staging system proposed by the International Mesothelioma Interest Group (IMIG) in 1995.

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node
metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**AJCC/IMIG Staging System for Diffuse Malignant Pleural Mesothelioma**

**Primary Tumor (T)**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor involves ipsilateral parietal pleura, with or without focal involvement of visceral pleura</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura. No involvement of the visceral pleura</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura, with focal involvement of the visceral pleura</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor involves any of the ipsilateral pleural surfaces with at least 1 of the following:</td>
</tr>
<tr>
<td></td>
<td>- confluent visceral tumor (including fissure)</td>
</tr>
<tr>
<td></td>
<td>- invasion of diaphragmatic muscle</td>
</tr>
<tr>
<td></td>
<td>- invasion of lung parenchyma</td>
</tr>
<tr>
<td>T3#</td>
<td>Tumor involves any of the ipsilateral pleural surfaces, with at least 1 of the following:</td>
</tr>
<tr>
<td></td>
<td>- invasion of the endothoracic fascia</td>
</tr>
<tr>
<td></td>
<td>- invasion into mediastinal fat</td>
</tr>
<tr>
<td></td>
<td>- solitary focus of tumor invading the soft tissues of the chest wall</td>
</tr>
<tr>
<td></td>
<td>- non-transmural involvement of the pericardium</td>
</tr>
<tr>
<td>T4##</td>
<td>Tumor involves any of the ipsilateral pleural surfaces, with at least 1 of the following:</td>
</tr>
<tr>
<td></td>
<td>- diffuse or multifocal invasion of soft tissues of the chest wall</td>
</tr>
<tr>
<td></td>
<td>- any involvement of rib</td>
</tr>
<tr>
<td></td>
<td>- invasion through the diaphragm to the peritoneum</td>
</tr>
<tr>
<td></td>
<td>- invasion of any mediastinal organ(s)</td>
</tr>
<tr>
<td></td>
<td>- direct extension to the contralateral pleura</td>
</tr>
<tr>
<td></td>
<td>- invasion into the spine</td>
</tr>
<tr>
<td></td>
<td>- extension to the internal surface of the pericardium</td>
</tr>
<tr>
<td></td>
<td>- pericardial effusion with positive cytology</td>
</tr>
<tr>
<td></td>
<td>- invasion of the myocardium</td>
</tr>
<tr>
<td></td>
<td>- invasion of the brachial plexus</td>
</tr>
</tbody>
</table>

# T3 describes locally advanced, but potentially resectable tumor

## T4 describes locally advanced, technically unresectable tumor
Regional Lymph Nodes (N)

NX  Regional lymph nodes cannot be assessed
N0  No regional lymph node metastases
N1  Metastases in the ipsilateral bronchopulmonary and/or hilar lymph node(s)
N2  Metastases in the subcarinal lymph node(s) and/or the ipsilateral internal mammary or mediastinal lymph node(s)
N3  Metastases in the contralateral mediastinal, internal mammary, or hilar lymph node(s) and/or the ipsilateral or contralateral supraclavicular or scalene lymph node(s)

Distant Metastasis (M)

MX  Distant metastasis cannot be assessed
M0  No distant metastasis
M1  Distant metastasis

Stage Groupings

Stage I  T1  N0  M0
Stage IA T1a N0  M0
Stage IB T1b N0  M0
Stage II T2  N0  M0
Stage III T1,T2 N1  M0
       T1,T2 N2  M0
       T3  N0,N1,N2 M0
Stage IV T4  Any N  M0
        Any T N3  M0
        Any T Any N M1

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.
Additional Descriptors

**Residual Tumor (R)**
Tumor remaining in a patient after therapy with curative intent (e.g., surgical resection for cure) is categorized by a system known as R classification, shown below.

RX  Presence of residual tumor cannot be assessed  
R0  No residual tumor  
R1  Microscopic residual tumor  
R2  Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**Vessel Invasion**
By AJCC/UICC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. In all other cases, lymphatic and venous invasion by tumor are coded separately as follows.

**Lymphatic Vessel Invasion (L)**
LX  Lymphatic vessel invasion cannot be assessed  
L0  No lymphatic vessel invasion  
L1  Lymphatic vessel invasion

**Venous Invasion (V)**
VX  Venous invasion cannot be assessed  
V0  No venous invasion  
V1  Microscopic venous invasion  
V2  Macroscopic venous invasion

**References**


**Bibliography**


